Rubin: FDA helped Merck figure out how to channel science into regulatory approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The idea that led to the site-agnostic indication for Keytruda (pembrolizumab) came from the academic oncologists, who ended up defining the biologic mechanism of activity of this class of drugs.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

Paul Goldberg
Editor & Publisher

Login